Phase 3 Oesophageal Cancer Trial, Recruiting NCT05357846 Sponsor: Sun Yat-sen University Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 3 Oesophageal Cancer Trial, Recruiting

NCT05357846
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with a specific type of esophageal cancer (squamous cell carcinoma of the chest portion of the esophagus) at a stage that doctors consider potentially removable by surgery, meeting specific staging criteria (confirm with trial site)
  • People who have not received any cancer treatment before
  • People whose doctors estimate they have more than 6 months life expectancy
  • People aged between 18 and 70 years
  • People whose blood test results show healthy levels of white blood cells, neutrophils, platelets, and hemoglobin, and whose liver and kidneys are functioning normally
  • People with a good general level of physical functioning, rated 0 or 1 on the WHO performance scale (meaning fully active or able to carry out light work)
  • People who have signed a consent form agreeing to take part

Who may not be able to join:

  • People who have already had any cancer treatment
  • People known or suspected to have an allergy to the study drugs sintilimab, paclitaxel (taxol), or cisplatin
  • People who have a bleeding or haemorrhage disorder
  • People whose health means they would not be able to safely undergo surgery
  • People who are pregnant or breastfeeding
  • People who are unable to give informed consent due to psychological, family, social, or other reasons
  • People who already have nerve damage in their hands or feet rated at level 2 or above on a standard severity scale
  • People who have or have had another type of cancer, except for certain treated skin cancers, early-stage cervical cancer confined to the surface, or early prostate cancer that has been fully cured
  • People who have had diabetes for more than 10 years and whose blood sugar levels have not been well controlled
  • People with serious heart, lung, liver, kidney, blood, or immune system conditions, or significant unintended weight loss and muscle wasting, that would make chemotherapy, radiotherapy, or surgery unsafe
  • People with a history of autoimmune diseases, immune deficiency conditions, or who have had an organ transplant or bone marrow transplant
  • People with a history of scarring lung disease or non-infection-related lung inflammation
  • People with an active tuberculosis (TB) infection, a TB infection in the past year, or a past TB infection that was not properly treated
  • People with active hepatitis B (at levels above a specified threshold) or hepatitis C (confirmed by a positive antibody test)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: HONG YANG, Sun Yat-Sen University Cancer Center

Phone: 8602087343

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 November 2022
Est. completion
1 January 2031

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov